Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | COMT | P21964 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11027996 | 0.80 | ELANE (0.48) | ELANEKDM4ENPC1HTTRAB9A | |
| SCHEMBL28462480 | 0.77 | ELANE (0.44) | ELANEKDM4E | |
| SCHEMBL28673352 | 0.72 | ELANE (0.49) | ELANEKDM4EHTT | |
| SCHEMBL30069016 | 0.72 | ELANE (0.49) | ELANEKDM4EHTT | |
| SCHEMBL21408838 | 0.72 | KDM4E (0.55) | KDM4ENPSR1 | |
| SCHEMBL15414568 | 0.70 | KDM4E (0.37) | COMTKDM4ENPC1ALOX12HTT | |
| SCHEMBL28994902 | 0.69 | ELANE (0.59) | ELANEKDM4EHTT | |
| SCHEMBL28465215 | 0.69 | ELANE (0.43) | ELANEKDM4E | |
| SCHEMBL19095663 | 0.69 | ELANE (0.46) | ELANEKDM4E | |
| SCHEMBL3210378 | 0.69 | PARP1 (0.49) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190701-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190701-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | ELANE 1325/4885PDE4A 2112/4885KCNH2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.